32066-29-8

Basic information

• Product Name: 4-HYDROXYBENZOYLACETIC ACID METHYL ESTER
• Synonyms: hydroxybenzoylaceticacidmethylester;METHYL (4-HYDROXYBENZOYL)ACETATE;4-HYDROXYBENZOYLACETIC ACID METHYL ESTER;4-HYDROXYBENZOYLACETIC ACID METHYL ESTER 93+%;Benzenepropanoic acid, 4-hydroxy-b-oxo-, Methyl ester;methyl 3-(4-hydroxyphenyl)-3-oxopropanoate
• CAS NO: 32066-29-8
• Molecular Formula: C₁₀H₁₀O₄
• Molecular Weight: 194.18
• Mol File: 32066-29-8.mol
• Article Data: 4

Chemical Properties

• Melting Point: 90°C
• Boiling Point: 340°C at 760 mmHg
• Flash Point: 135.5°C
• Appearance: /
• Density: 1.245g/cm³
• Vapor Pressure: 4.48E-05mmHg at 25°C
• Refractive Index: 1.543
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 7.79±0.15(Predicted)
• CAS DataBase Reference: 4-HYDROXYBENZOYLACETIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXYBENZOYLACETIC ACID METHYL ESTER(32066-29-8)
• EPA Substance Registry System: 4-HYDROXYBENZOYLACETIC ACID METHYL ESTER(32066-29-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: 24/25
• Hazardous Substances Data: 32066-29-8(Hazardous Substances Data)

Usage

General Description

4-HYDROXYBENZOYLACETIC ACID METHYL ESTER is a chemical compound that belongs to the class of organic compounds known as hydroxybenzoic acid esters. It is an ester derivative of 4-hydroxybenzoylacetate and is commonly used as a pharmaceutical intermediate. 4-HYDROXYBENZOYLACETIC ACID METHYL ESTER is often used in the production of various drugs and other pharmaceutical products due to its ability to modify and enhance the properties of active ingredients. It may also have potential applications in the field of organic synthesis and chemical research.

InChI:InChI=1/C10H10O4/c1-14-10(13)6-9(12)7-2-4-8(11)5-3-7/h2-5,11H,6H2,1H3

Upstream product

• 22027-50-5 methyl 3-(4-methoxybenzoyl)acetate 
• 705939-73-7 methyl 3-[4-(benzyloxy)phenyl]-3-oxopropanoate 
• 54696-05-8 4'-benzyloxy-acetophenone 
• 99-93-4 4-Hydroxyacetophenone 
• 616-38-6 carbonic acid dimethyl ester 

Downstream Products

• 1356599-24-0 (3E,3Z)-3-(methoxyimino)-3-{4-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]phenyl}propanoic acid 
• 1356599-74-0 3-hydroxy-3-{4-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]phenyl}propanoic acid 
• 1356599-76-2 (3Z)-3-{4-[(4-{[(2E,2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]phenyl}-3-[(prop-2-en-1-yloxy)imino]propanoic acid 
• 1356600-42-4 methyl (3E,3Z)-3-(4-hydroxyphenyl)-3-(methoxyimino)propanoate 
• 1356602-45-3 methyl 3-{4-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]phenyl}-3-oxopropanoate 
• 1404447-06-8 5-(4-hydroxyphenyl)-2-methyl-3-phenylpyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 18274-81-2 desmethyl anethole trithione 
• 1441066-97-2 N-(4-cyanophenyl)-5,5-difluoro-2-oxo-4-p-tolyl-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide 
• 1441049-59-7 8-(4-methoxyphenyl)-6-oxo-4-(4-(4,4,4-trifluorobutoxy)phenyl)-4-(trifluoro-methyl)-5-azaspiro[2.5]oct-7-ene-7-carbonitrile 
• 1441058-68-9 5,5-difluoro-2-oxo-4-p-tolyl-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid 
• 1441058-64-5 ethyl 5,5-difluoro-2-oxo-4-p-tolyl-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxylate 
• 1441058-66-7 3-amino-2,2,4,4,4-pentafluoro-1-p-tolyl-3-(4-(4,4,4-trifluorobutoxy)phenyl)butan-1-one 
• 1441058-60-1 2-methyl-N-(1,1,1,3,3-pentafluoro-4-oxo-4-p-tolyl-2-(4-(4,4,4-trifluorobutoxy)phenyl)butan-2-yl)propane-2-sulfinamide 
• 1441058-58-7 N-benzyl-2-methyl-N-(1,1,1,3,3-pentafluoro-4-oxo-4-(piperidin-1-yl)-2-(4-(4,4,4-trifluorobutoxy)phenyl)butan-2-yl)propane-2-sulfinamide 

Relevant articles and documents

Compound and its as L-type calcium channel blocker or/and application of acetylcholine esterase inhibitors

Disclosed in this invention are compounds and the uses as L-type calcium channel blocker and/or acetylcholinesterase inhibitor thereof. The uses of said compounds in the manufactures of a medicament for the treatment of cardiovascular diseases, apoplexy or senile dementia are also disclosed in the present invention.

AGONISTS OF GPR40

The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are there-fore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.